NYSE:LLY

Eli Lilly and Competitors

$243.50
-1.83 (-0.75 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$242.63
$245.95
50-Day Range
$199.13
$246.51
52-Week Range
$129.21
$248.40
Volume1.91 million shs
Average Volume2.32 million shs
Market Capitalization$233.52 billion
P/E Ratio36.40
Dividend Yield1.40%
Beta0.26

Eli Lilly and (NYSE:LLY) Vs. JNJ, PFE, ABBV, MRK, BMY, and ZTS

Should you be buying LLY stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Eli Lilly and, including Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), and Zoetis (ZTS).

Eli Lilly and (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Earnings and Valuation

This table compares Eli Lilly and and Johnson & Johnson's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$24.54 billion9.52$6.19 billion$7.9330.71
Johnson & Johnson$82.58 billion5.49$14.71 billion$8.0321.44

Johnson & Johnson has higher revenue and earnings than Eli Lilly and. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Eli Lilly and and Johnson & Johnson, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and021112.93
Johnson & Johnson02702.78

Eli Lilly and currently has a consensus target price of $231.2857, indicating a potential downside of 5.02%. Johnson & Johnson has a consensus target price of $190.3750, indicating a potential upside of 10.55%. Given Johnson & Johnson's higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Eli Lilly and.

Dividends

Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.5%. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 1 consecutive years and Johnson & Johnson has increased its dividend for 59 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

81.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 66.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Eli Lilly and and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and23.91%132.28%16.36%
Johnson & Johnson19.92%37.78%14.12%

Risk & Volatility

Eli Lilly and has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Summary

Eli Lilly and beats Johnson & Johnson on 10 of the 18 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Pfizer and Eli Lilly and's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$41.91 billion5.72$9.62 billion$2.2219.28
Eli Lilly and$24.54 billion9.52$6.19 billion$7.9330.71

Pfizer has higher revenue and earnings than Eli Lilly and. Pfizer is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Pfizer and Eli Lilly and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer010202.17
Eli Lilly and021112.93

Pfizer currently has a consensus price target of $43.0833, indicating a potential upside of 0.64%. Eli Lilly and has a consensus price target of $231.2857, indicating a potential downside of 5.02%. Given Pfizer's higher possible upside, equities research analysts plainly believe Pfizer is more favorable than Eli Lilly and.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.6%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Pfizer pays out 70.3% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years.

Institutional & Insider Ownership

64.1% of Pfizer shares are owned by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Pfizer and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer23.06%26.93%10.83%
Eli Lilly and23.91%132.28%16.36%

Volatility and Risk

Pfizer has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats Pfizer on 12 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares AbbVie and Eli Lilly and's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$45.80 billion4.48$4.62 billion$10.5611.01
Eli Lilly and$24.54 billion9.52$6.19 billion$7.9330.71

Eli Lilly and has lower revenue, but higher earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for AbbVie and Eli Lilly and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie111202.79
Eli Lilly and021112.93

AbbVie currently has a consensus price target of $121.6733, indicating a potential upside of 4.62%. Eli Lilly and has a consensus price target of $231.2857, indicating a potential downside of 5.02%. Given AbbVie's higher possible upside, equities research analysts plainly believe AbbVie is more favorable than Eli Lilly and.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. AbbVie pays out 49.2% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

66.0% of AbbVie shares are owned by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares AbbVie and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie10.28%136.75%12.95%
Eli Lilly and23.91%132.28%16.36%

Volatility and Risk

AbbVie has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats AbbVie on 10 of the 18 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Merck & Co., Inc. and Eli Lilly and's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$47.99 billion4.06$7.07 billion$5.9412.94
Eli Lilly and$24.54 billion9.52$6.19 billion$7.9330.71

Merck & Co., Inc. has higher revenue and earnings than Eli Lilly and. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Merck & Co., Inc. and Eli Lilly and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.03802.73
Eli Lilly and021112.93

Merck & Co., Inc. currently has a consensus price target of $94.7238, indicating a potential upside of 23.23%. Eli Lilly and has a consensus price target of $231.2857, indicating a potential downside of 5.02%. Given Merck & Co., Inc.'s higher possible upside, equities research analysts plainly believe Merck & Co., Inc. is more favorable than Eli Lilly and.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Merck & Co., Inc. pays out 43.8% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years.

Institutional & Insider Ownership

71.7% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Merck & Co., Inc. and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.11.48%53.80%16.15%
Eli Lilly and23.91%132.28%16.36%

Volatility and Risk

Merck & Co., Inc. has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats Merck & Co., Inc. on 11 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 2.9%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Bristol-Myers Squibb pays out 30.4% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Bristol-Myers Squibb and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-11.44%37.76%13.14%
Eli Lilly and23.91%132.28%16.36%

Earnings and Valuation

This table compares Bristol-Myers Squibb and Eli Lilly and's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$42.52 billion3.55$-9,015,000,000.00$6.4410.54
Eli Lilly and$24.54 billion9.52$6.19 billion$7.9330.71

Eli Lilly and has lower revenue, but higher earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Bristol-Myers Squibb and Eli Lilly and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb03912.85
Eli Lilly and021112.93

Bristol-Myers Squibb currently has a consensus price target of $74.30, indicating a potential upside of 9.47%. Eli Lilly and has a consensus price target of $231.2857, indicating a potential downside of 5.02%. Given Bristol-Myers Squibb's higher possible upside, equities research analysts plainly believe Bristol-Myers Squibb is more favorable than Eli Lilly and.

Institutional & Insider Ownership

71.5% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats Bristol-Myers Squibb on 11 of the 16 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Zoetis pays out 26.0% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years.

Profitability

This table compares Zoetis and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.30%55.11%14.70%
Eli Lilly and23.91%132.28%16.36%

Valuation & Earnings

This table compares Zoetis and Eli Lilly and's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.68 billion14.42$1.64 billion$3.8552.65
Eli Lilly and$24.54 billion9.52$6.19 billion$7.9330.71

Eli Lilly and has higher revenue and earnings than Zoetis. Eli Lilly and is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Zoetis and Eli Lilly and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis06702.54
Eli Lilly and021112.93

Zoetis presently has a consensus price target of $188.75, suggesting a potential downside of 6.88%. Eli Lilly and has a consensus price target of $231.2857, suggesting a potential downside of 5.02%. Given Eli Lilly and's stronger consensus rating and higher possible upside, analysts clearly believe Eli Lilly and is more favorable than Zoetis.

Institutional & Insider Ownership

90.0% of Zoetis shares are held by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Zoetis has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats Zoetis on 10 of the 17 factors compared between the two stocks.

Ad MarketBeat
30 Days of MarketBeat All Access for $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more.

Eli Lilly and Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.6$172.20-0.0%$453.47 billion$82.58 billion25.89Analyst Report
Pfizer logo
PFE
Pfizer
2.8$42.81-0.0%$239.64 billion$41.91 billion18.37Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
AbbVie logo
ABBV
AbbVie
3.2$116.30-2.2%$205.41 billion$45.80 billion31.35Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.8$76.87-0.1%$194.64 billion$47.99 billion35.10Earnings Announcement
Dividend Announcement
Analyst Report
Analyst Revision
News Coverage
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.5$67.87-0.4%$150.81 billion$42.52 billion-29.90Earnings Announcement
Analyst Report
Short Interest Increase
Analyst Revision
Zoetis logo
ZTS
Zoetis
2.3$202.70-0.7%$96.24 billion$6.68 billion54.64Upcoming Earnings
Short Interest Decrease
Royalty Pharma logo
RPRX
Royalty Pharma
3.0$38.20-0.1%$23.19 billion$2.12 billion23.88Analyst Report
Insider Selling
News Coverage
High Trading Volume
High Trading Volume
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$100.02-2.6%$22.48 billion$2.20 billion86.22Upcoming Earnings
Analyst Upgrade
Insider Selling
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
3.1$169.52-0.6%$9.65 billion$2.36 billion18.59Upcoming Earnings
Perrigo logo
PRGO
Perrigo
2.2$48.03-0.3%$6.41 billion$5.06 billion-28.25
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
2.2$15.79-1.7%$2.88 billion$152.91 million-6.61Upcoming Earnings
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.4$58.95-1.9%$2.60 billion$429.65 million17.76Upcoming Earnings
Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
2.4$20.77-2.3%$2.42 billion$353.87 million27.33Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
2.6$26.33-4.0%$1.40 billion$520.40 million12.72Upcoming Earnings
Analyst Upgrade
Short Interest Decrease
News Coverage
Gap Up
Endo International logo
ENDP
Endo International
2.2$5.06-1.2%$1.18 billion$2.90 billion12.65Upcoming Earnings
Zogenix logo
ZGNX
Zogenix
2.1$16.21-0.6%$904.73 million$13.64 million-3.77Upcoming Earnings
Omeros logo
OMER
Omeros
2.1$14.50-2.0%$903.76 million$73.81 million-5.94Unusual Options Activity
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
3.0$3.76-0.0%$370.44 million$156.47 million15.04Upcoming Earnings
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
2.1$5.20-4.2%$244.03 million$46.92 million-2.71Gap Up
Lannett logo
LCI
Lannett
2.5$4.64-1.1%$192.31 million$545.74 million-0.94News Coverage
Assembly Biosciences logo
ASMB
Assembly Biosciences
2.1$3.47-0.0%$139.35 million$79.11 million-2.04Upcoming Earnings
Short Interest Decrease
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
1.5$3.25-4.6%$48.91 million$37.44 million-23.21Short Interest Decrease
Gap Up
This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.